Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Oct 1:316:240-241.
doi: 10.1016/j.ijcard.2020.06.059. Epub 2020 Jul 4.

Suboptimal management of dyslipidemia in everyday clinical practice: Alarming signals from real-world data

Vasilios G Athyros  1 , Konstantinos Stavropoulos  2 , Konstantinos P Imprialos  2 , Michael Doumas  2
Affiliations
Editorial

Suboptimal management of dyslipidemia in everyday clinical practice: Alarming signals from real-world data

Vasilios G Athyros et al. Int J Cardiol. .
No abstract available

Keywords: Atherosclerotic cardiovascular disease; Cardiovascular risk; Dyslipidemia; Lipid-lowering agent; Low density lipoprotein-cholesterol; Statin.

PubMed Disclaimer

Comment on

References

    1. Task Force Members, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies ESC/EAS guidelines for the Management of Dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290(2019):140–205. doi: 10.1016/j.atherosclerosis.2019.08.014. - DOI - PubMed
    1. Dykun, I., Mahabadi, A.A., Rassaf, T. A clinical perspective on the 2019 ESC/EAS guidelines for the management of dyslipidaemias: PCSK-9 inhibitors for all? Eur. Heart J., (2020), ehaa005. doi: 10.1093/eurheartj/ehaa005 - DOI - PubMed
    1. De Luca L., Arca M., Temporelli P.L., Meessen J., Riccio C., Bonomo P., Colavita A.R., Gabrielli D., Gulizia M.M., Colivicchi F., the START Investigators Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS Guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: insights from the START registry. Int. J. Cardiol. 2020 (In press) - PubMed
    1. Annemans L., Azuri J., Al-Rasadi K., Al-Zakwani I., Daclin V., Mercier F., Danchin N. Healthcare resource utilization in patients on lipid-lowering therapies outside Western Europe and North America: findings of the cross-sectional observational International ChoLesterol management Practice Study (ICLPS) Lipids Health Dis. 2020;19:64. doi: 10.1186/s12944-020-01235-5. (Online ahead of print) - DOI - PMC - PubMed
    1. Tahkola A., Korhonen P., Kautiainen H., Niiranen T., Mäntyselkä P. Lifetime risk assessment in cholesterol management among hypertensive patients: observational cross-sectional study based on electronic health record data. BMC Fam. Pract. 2020;21:62. doi: 10.1186/s12875-020-01138-5. - DOI - PMC - PubMed

Substances